The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Tigecycline
Abstract
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently available drugs has become paramount. Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetracyclines. In vitro testing has revealed that tigecycline has activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and many species of multidrug-resistant Gram-negative bacteria, although resistance to tigecycline by Pseudomonas aeruginosa and reduced susceptibility among Proteus species do occur. Tigecycline is being evaluated in multicentre Phase III clinical trials for therapy of many serious and life-threatening infections in which multidrug-resistant bacterial organisms may be found. Tigecycline appears to hold promise as a novel expanded spectrum antibiotic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Ribosomal Protection Proteins and Their Mechanism ofTetracyclineResistance
Connell, S. R., Tracz, D. M., Nierhaus, K. H., & Taylor, D. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3675-3681.2003 · Cited by 449
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Melzer, M., Eykyn, S. J., Gransden, W. R., & Chinn, S. (2003) · Clinical Infectious Diseases · doi:10.1086/379321 · Cited by 241
Bozdogan, B. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg457 · Cited by 225
Henwood, C. J., Gatward, T., Warner, M., James, D., Stockdale, M. W., Spence, R. P., Towner, K. J., Livermore, D. M., & Woodford, N. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.3.479 · Cited by 213
Gales, A. C., & Jones, R. N. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00092-9 · Cited by 189
Buckingham, S. C., McDougal, L. K., Cathey, L. D., Comeaux, K., Craig, A. S., Fridkin, S. K., & Tenover, F. C. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000131981.67342.c4 · Cited by 181
van Ogtrop, M. L., Andes, D., Stamstad, T. J., Conklin, B., Weiss, W. J., Craig, W. A., & Vesga, O. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.943-949.2000 · Cited by 179
Origins of Community Strains of Methicillin-Resistant Staphylococcus aureus
Charlebois, E. D., Perdreau-Remington, F., Kreiswirth, B., Bangsberg, D. R., Ciccarone, D., Diep, B. A., Ng, V. L., Chansky, K., Edlin, B., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/421090 · Cited by 174
Petersen, P. J., Bradford, P. A., Weiss, W. J., Murphy, T. M., Sum, P. E., & Projan, S. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2595-2601.2002 · Cited by 169
Kenny, G. E., & Cartwright, F. D. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2604-2608.2001 · Cited by 167
Visalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165
Bauer, G. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh125 · Cited by 163
Reynolds, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh232 · Cited by 162
Zhanel, G. G., Palatnick, L., Nichol, K. A., Bellyou, T., Low, D. E., & Hoban, D. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1867-1874.2003 · Cited by 161
Bouchillon, S. K., Johnson, B., Hoban, D., Johnson, J. L., Dowzicky, M. J., Wu, D., Visalli, M. A., & Bradford, P. A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.01.010 · Cited by 141
In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain
Betriú, C., Rodríguez-Avial, I., Sánchez, B. A., Gómez, M., Alvarez, J. A. O., & Picazo, J. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.892-895.2002 · Cited by 127
Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936)
Hirata, T., Saito, A., Nishino, K., Tamura, N., & Yamaguchi, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2179-2184.2004 · Cited by 124
Preclinical Pharmacology of GAR‐936, a Novel Glycylcycline Antibacterial Agent
Projan, S. J. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.14.219s.35046 · Cited by 123
Glycylcyclines: third-generation tetracycline antibiotics
Chopra, I. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00081-9 · Cited by 122
Hiramatsu, K., Okuma, K., Xue, X., Yamamoto, M., Hori, S., & Kapi, M. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200208000-00009 · Cited by 121
Biedenbach, D. J., Beach, M. L., & Jones, R. N. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(01)00269-3 · Cited by 102
Zhanel, G. G., Palatnick, L., Nichol, K. A., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1875-1881.2003 · Cited by 98
In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria
Boucher, H. W., Wennersten, C. B., & Eliopoulos, G. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2225-2229.2000 · Cited by 98
Tuckman, M., Petersen, P. J., & Projan, S. J. (2000) · Microbial Drug Resistance · doi:10.1089/mdr.2000.6.277 · Cited by 84
Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis
Murphy, T. M., Deitz, J. M., Petersen, P. J., Mikels, S. M., & Weiss, W. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3022-3027.2000 · Cited by 80
Fritsche, T. R., Kirby, J. T., & Jones, R. N. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.03.002 · Cited by 74
Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., & Tyrrell, K. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2747-2751.2000 · Cited by 72
Recent Developments in Tetracycline Antibiotics
Sum, P., Sum, F. W., & Projan, S. J. (1970) · Current Pharmaceutical Design · doi:10.2174/138161280401221007113202 · Cited by 71
Hoellman, D. B., Pankuch, G. A., Jacobs, M. R., & Appelbaum, P. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1085-1088.2000 · Cited by 65
Labthavikul, P., Petersen, P. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3967-3969.2003 · Cited by 55
Deshpande, L. M., Gales, A. C., & Jones, R. N. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00355-7 · Cited by 39
Nannini, E. C., Pai, S. R., Singh, K. V., & Murray, B. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.529-532.2003 · Cited by 37
Disk diffusion susceptibility test development for the new glycylcycline, GAR-936
Jones, R. N. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00090-5 · Cited by 31
Antimicrobial susceptibility of Gram-positive bacteria: What's current, what's anticipated?
Johnson, A. P., Livermore, D. M., & Tillotson, G. (2001) · Journal of Hospital Infection · doi:10.1016/s0195-6701(01)90029-5 · Cited by 17
Ehrhardt, A. F., & Russo, R. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01029-4 · Cited by 11
Cited by
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
Infections associated with orthopedic implants
Trampuz, A., & Widmer, A. F. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000235161.85925.e8 · Cited by 542
Prospects for plant-derived antibacterials
Lewis, K., & Ausubel, F. M. (2006) · Nature Biotechnology · doi:10.1038/nbt1206-1504 · Cited by 474
Selenium nanoparticles: a review on synthesis and biomedical applications
Bisht, N., Phalswal, P., & Khanna, P. K. (2022) · Materials Advances · doi:10.1039/d1ma00639h · Cited by 384
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Metadata
- Authors
- Pankey, G. A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-22
- Volume
- 56
- Issue
- 3
- Pages
- 470-480
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W4211198655
- Cited by
- 301
- References
- 42
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.